| Today's Big NewsApr 6, 2023 |
| By Nick Paul Taylor Quince Therapeutics is trying to make itself a less appetizing bite for potential buyers as it works to fend off an unsolicited buyout bid from Echo Lake Capital. The “poison pill” is intended to deter investors from accumulating stock on the open market and will kick in once they buy a set percentage of the shares. |
|
|
|
By Max Bayer The FDA has approved 12 gene therapies so far, and the agency's top drug regulator wants to see the road ahead illuminated with green lights. |
By Max Bayer AbbVie is revising down its earnings forecast for the year due to a $150 million IPR&D charge. The company's original earnings projections presented in February were already lower than Wall Street's projections. |
By Nick Paul Taylor Exelixis is standing its ground in the face of a full-throated attack by an activist investor, defending its record in response to accusations that it has presided over an undisciplined and incoherent R&D model. |
By Annalee Armstrong How exactly are baby human adenoviruses born? Scientists have wondered about this question for a long time, and new research published this week in Nature revealed the process that viral proteins use to replicate—which could lead to better gene therapy delivery and other new therapeutics. |
By Joseph Keenan ConcertAI, which specializes in software and real-world evidence for clinical trials, has unveiled the latest version of its clinical trial optimization product. |
By Andrea Park Almost exactly three years after taking on the role, Ken Reali has stepped down from his post as chief executive of Bioventus. |
By Zoey Becker Thermos Fisher Scientific plans to close its Princeton, New Jersey, plant and lay off 113 workers. The company is making the move to “remain in line with current manufacturing volume demands," a spokesperson said. |
By Conor Hale After reversing course on a SPAC deal last year, cardiac diagnostic developer HeartFlow has picked up what could hardly be considered a consolation prize. |
By Kevin Dunleavy After losing a patent case in court on Wednesday, GSK will have to surrender a portion of its sales of its ovarian cancer drug Zejula to AstraZeneca. The case involves technology GSK subsidiary Tesaro licensed from AZ 11 years ago. |
By Robert King A new study in Health Affairs finds a decline in Medicare Advantage payments would only lead to a modest impact on benefits for seniors. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss how 2023 is shaping up to be much the same as last year when it comes to financing trends for biotechs. We also cover Emergent's Narcan winning the first over-the-counter approval for an opioid-overdose drug and more of this week's top headlines. |
|
|---|
|
|
| Whitepaper The preclinical hematotoxicity screening method that helps clients eliminate bad players earlier in the drug development process Sponsored by: ReachBio | The Cell Biology Experts™ |
| Whitepaper We’ve identified four must-have tools to manage today’s scientific information chaos. How many are you utilizing? Sponsored By: CCC |
| Whitepaper How advanced medicines commercial readiness differs and the resources needed to maximize potential. Sponsored by: Herspiegel Consulting |
| WhitepaperThis paper outlines an approach that digital health / therapeutics companies can use when developing a go-to-market strategy for the complex US market. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
| WhitepaperFor sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperHow can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
